Dry Eye Improvement from Single TearCare Treatment Sustained Through 12 MonthsDecember 27th 2022
According to the company, clinical outcomes for 78 dry eye patients treated at a single center, the Cleveland Eye Clinic, showcased the duration of efficacy of a single, first-time treatment of MGD using the TearCare System.
Phase 3 Trial Shows Benefit of Empagliflozin for Pediatric Type 2 DiabetesDecember 22nd 2022
Eli Lilly and Company and Boehringer Ingelheim announced their SGLT2 inhibitor, empagliflozin, was associated with statistically significant reductions in HbA1c relative to placebo therapy among a population of pediatric patients with type 2 diabetes in the DINAMO trial.
Chronic Kidney Disease Rates in People with Diabetes Considered "Troubling"October 17th 2022
An analysis of data from more than 640,000 people with diabetes recorded between 2015-2020 is providing new insight into what study investigators are calling "troubling" trends in the incidence of CKD in the face a growing diabetes epidemic.
Type 2 Diabetes in Young Patients Spiked in Year 1 of COVID-19 PandemicAugust 29th 2022
Using electronic medical record data from 2018-2020 obtained from 24 medical centers across the US, including Johns Hopkins, University of Colorado, and Mayo Clinic institutions, a new study suggests rates of youth onset type 2 diabetes increased 77% during the first year of the pandemic.
CVD Risk in Type 2 Diabetes May Be Impacted by GnRH Agonists for Prostate CancerAugust 10th 2022
New research suggests there was a 53% greater 5-year risk of cardiovascular disease in men with type 2 diabetes who received a GnRH agonist for prostate cancer compared with their counterparts who did not receive GnRH agonists.